EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Bolusing IV Administration Sets With Monoclonal Antibodies Reduces Cost and Chair Time: A Randomized Controlled Trial

Francesca Boyte, Brighid Scanlon, Robyn Matthews, Elise Button, Lee Jones, Therese Hayes, Grant Partridge, Michael Smith, Glen Andrew Kennedy, Melissa Eastgate, Nicole Clare Gavin

Clinical Journal of Oncology Nursing · 2024

DOI: 10.1188/24.cjon.e9-e15 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Journal of Oncology Nursing, 2024. Verfasst von Francesca Boyte und 10 weiteren Autor:innen. Beteiligte Einrichtung: Royal Brisbane and Women's Hospital. Hauptthemen laut MEDLINE: Antibodies, Monoclonal.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Monoclonal antibodies are widely used anticancer therapies. Increasing demand for ambulatory care necessitates exploration of efficiency measures. OBJECTIVES: The primary objective was to evaluate the impacts on chair time and associated cost of priming IV administration sets with a bolus of the prescribed monoclonal antibody drugs. A secondary objective was to assess the associated incidence of hypersensitivity reactions. METHODS: A large tertiary hospital in Brisbane, Australia, conducted a randomized controlled trial (N = 128) with a two-arm design. Included monoclonal antibodies were daratumumab, obinutuzumab, pembrolizumab, and nivolumab. FINDINGS: There was a statistically significant reduction in chair time for obinutuzumab, pembrolizumab, and nivolumab compared with the control. Findings suggest that this priming intervention reduces chair time and cost for some monoclonal antibody drugs. Future research could assess this practice in other oncology therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalHumansFemaleMaleMiddle AgedAgedAustraliaAdultAntineoplastic AgentsNeoplasmsAdministration, IntravenousTime Factors

Stichwörter der Autor:innen

IV administrationchair timecost savingmonoclonal antibodiespriming

Substanzen

Antibodies, MonoclonalAntineoplastic Agents

Autor:innen und Institutionen

  • Royal Brisbane and Women's Hospital.
  • Queensland University of Technology.
  • Memorial Sloan Kettering Cancer Center.

Zitieren

APA

Boyte, F., Scanlon, B., Matthews, R., Button, E., Jones, L., Hayes, T., Partridge, G., Smith, M., Kennedy, G. A., Eastgate, M., & Gavin, N. C. (2024). Bolusing IV Administration Sets With Monoclonal Antibodies Reduces Cost and Chair Time: A Randomized Controlled Trial. Clinical Journal of Oncology Nursing. https://doi.org/10.1188/24.cjon.e9-e15

Vancouver

Boyte F, Scanlon B, Matthews R, Button E, Jones L, Hayes T, et al. Bolusing IV Administration Sets With Monoclonal Antibodies Reduces Cost and Chair Time: A Randomized Controlled Trial. Clinical Journal of Oncology Nursing. 2024. doi:10.1188/24.cjon.e9-e15

BibTeX
@article{Boyte2024,
  author = {Boyte, Francesca and Scanlon, Brighid and Matthews, Robyn and Button, Elise and Jones, Lee and Hayes, Therese and Partridge, Grant and Smith, Michael and Kennedy, Glen Andrew and Eastgate, Melissa and Gavin, Nicole Clare},
  title = {Bolusing IV Administration Sets With Monoclonal Antibodies Reduces Cost and Chair Time: A Randomized Controlled Trial},
  journal = {Clinical Journal of Oncology Nursing},
  year = {2024},
  doi = {10.1188/24.cjon.e9-e15}
}
Kostenlos starten →